Search

Milind B Rajopadhye

from Westford, MA
Age ~65

Milind Rajopadhye Phones & Addresses

  • 21 Honeysuckle Rd, Westford, MA 01886 (978) 392-9536 (978) 846-2067
  • North Billerica, MA
  • North Chelmsford, MA

Business Records

Name / Title
Company / Classification
Phones & Addresses
Milind Rajopadhye
Director Chemistry
Visen Medical Inc
Commercial Physical Research, Nsk
45 Wiggins Ave, Bedford, MA 01730
(781) 932-6875

Publications

Us Patents

Radiopharmaceuticals For Imaging Infection And Inflammation

View page
US Patent:
6416733, Jul 9, 2002
Filed:
Oct 3, 1997
Appl. No.:
08/943659
Inventors:
John A. Barrett - Groton MA
Edward H. Cheesman - Lunenburg MA
Thomas D. Harris - Salem NH
Shuang Liu - Chelmsford MA
Milind Rajopadhye - Westford MA
Michael Sworin - Tyngsboro MA
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 5100
US Classification:
424 165, 424 169, 534 10
Abstract:
The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

Vitronectin Receptor Antagonist Pharmaceuticals

View page
US Patent:
6511648, Jan 28, 2003
Filed:
Dec 17, 1999
Appl. No.:
09/465300
Inventors:
Thomas D. Harris - Salem NH
Milind Rajopadhye - Westford MA
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 5100
US Classification:
424 165, 424 111, 424 169, 424 91, 424 94, 424 95, 530331
Abstract:
The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Vitronectin Receptor Antagonist Pharmaceuticals

View page
US Patent:
6511649, Jan 28, 2003
Filed:
Jun 21, 2000
Appl. No.:
09/599364
Inventors:
Thomas D. Harris - Salem NH, 03079
John A. Barrett - Groton MA, 01450
Milind Rajopadhye - Westford MA, 01886
International Classification:
A61K 5100
US Classification:
424 169, 424 111, 424 165, 424 91, 424 94, 424 95, 530331
Abstract:
The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Radiopharmaceuticals For Imaging Infection And Inflammation And For Imaging And Treatment Of Cancer

View page
US Patent:
6524554, Feb 25, 2003
Filed:
Apr 2, 1999
Appl. No.:
09/285280
Inventors:
David Scott Edwards - Burlington MA
Milind Rajopadhye - Westford MA
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 4904
US Classification:
424 94, 424 111, 424 165, 424 169, 424 91, 534 10, 534 14
Abstract:
The present invention provides novel radiopharmaceuticals comprising one to three pentapeptides, X X X X X , independently attached to a metal chelator or bonding moiety, C , to which is attached a Tc-99m, Re-186, or Re-188, optionally further comprising a linking group, L , between-the peptides and the chelator or bonding moiety. The pentapeptide sequence binds to the tuftsin receptor and is attached at the N-terminus to L or C. These radiopharmaceuticals are useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis.

Pharmaceuticals For The Imaging Of Angiogenic Disorders

View page
US Patent:
6537520, Mar 25, 2003
Filed:
Jun 21, 2000
Appl. No.:
09/599295
Inventors:
Milind Rajopadhye - Westford MA
D. Scott Edwards - Burlington MA
John A. Barrett - Groton MA
Thomas D. Harris - Samel NH
Stuart J. Heminway - Lowell MA
Shuang Liu - Chelmsford MA
Prahlad R. Singh - Arlington MA
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 5100
US Classification:
424 169, 424 111, 424 165, 424 91, 534 14
Abstract:
The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Vitronectin Receptor Antagonist Pharmaceuticals

View page
US Patent:
6558649, May 6, 2003
Filed:
Dec 17, 1999
Appl. No.:
09/466582
Inventors:
Edward H. Cheesman - Lunenberg MA
Michael Sworin - Tyngsboro MA
Milind Rajopadhye - Westford MA
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 5100
US Classification:
424 169, 540504, 540513, 424 111, 424 165, 424 91, 514183
Abstract:
The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Vitronectin Receptor Antagonist Pharmaceuticals

View page
US Patent:
6569402, May 27, 2003
Filed:
Jun 21, 2000
Appl. No.:
09/599365
Inventors:
Edward H. Cheesman - Lunenberg MA
John A. Barrett - Groton MA
Milind Rajopadhye - Westford MA
Michael Sworin - Tyngsboro MA
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 500
US Classification:
424 165, 424 111, 424 91, 534 14
Abstract:
The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Matrix Metalloproteinase Inhibitors

View page
US Patent:
6656448, Dec 2, 2003
Filed:
Feb 14, 2001
Appl. No.:
09/783249
Inventors:
Milind Rajopadhye - Westford MA
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 4900
US Classification:
424 91, 424 111, 424 165, 424 93, 424 9361, 424 936
Abstract:
Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties;a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.
Milind B Rajopadhye from Westford, MA, age ~65 Get Report